NovaBridge Biosciences annual free cash flow
2019
2020
2021
2022
2023
2024
2025
NovaBridge Biosciences Free Cash Flow (FCF) History (NBP)
NovaBridge Biosciences reported −$20.6M in free cash flow for fiscal 2025, an increase of $32.1M from the previous fiscal year.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$20.6M | $32.1M | — | — |
| 2024 | 2024-12-31 | −$52.7M | $131.2M | — | — |
| 2023 | 2023-12-31 | −$184.0M | −$22.0M | — | −29107.91% |
| 2022 | 2022-12-31 | −$162.0M | −$4.6M | — | — |
| 2021 | 2021-12-31 | −$157.4M | −$222.6M | — | −1139.48% |
| 2020 | 2020-12-31 | $65.2M | $191.7M | — | +27.59% |
| 2019 | 2019-12-31 | −$126.4M | — | — | −2934.23% |
NovaBridge Biosciences quarterly free cash flow
Q3.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $1.8M | — | — | — |
| Q3 2024 | 2024-09-30 | $8.4M | — | — | — |
NovaBridge Biosciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $65.2M to −$20.6M, a net decrease of $85.8M. NovaBridge Biosciences's latest reported quarter, Q3 2025, generated $1.8M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review NovaBridge Biosciences filings at SEC.gov ↗